跳到正文
原文
Medical Xpress·· 1 天前AI 评分55

纯CBD油对智力障碍青少年行为问题无显著改善:双盲RCT发表于JAMA Pediatrics

CBD oil offers no behavioral benefit for youths with intellectual disability, new study finds

AI 导读

一项在澳大利亚三所儿童医院开展的双盲RCT(N=131,6–18岁)纳入伴严重行为问题的智力障碍儿童,随机分配至每日纯CBD油或匹配安慰剂,维持期8周。结果显示CB组平均激惹评分由32.2降至21.7,安慰剂组由30降至19.2,差异无统计学意义;焦虑、睡眠、社交退缩及养育压力均未见额外获益。

正文
CBD oil offers no behavioral benefit for youths with intellectual disability, finds new study
Researchers tested the effectiveness of pure CBD oil in easing behavioral problems in children and teenagers with intellectual disabilities. Credit: Pexels.

Cannabis contains two key compounds that act on the brain: cannabidiol (CBD) and tetrahydrocannabinol (THC). Although both interact with the body's endocannabinoid system, the outcomes of consuming them are poles apart. THC is the compound responsible for marijuana's intoxicating high and can sometimes trigger adverse effects, including psychosis. CBD, on the other hand, is associated with potential anxiety-relieving and anti-inflammatory effects. Despite limited evidence that it works, over the last decade, CBD-rich medical cannabis has gained popularity as a treatment for behavioral problems in children with autism spectrum disorder (ASD).

A recent study published in JAMA Pediatrics has put CBD to the test, investigating if the compound can help curb severe behavioral problems, including aggression and self-harm, in children and teenagers with intellectual disabilities.

After 10 weeks, the researchers compared the outcomes of children who received pure CBD oil daily for eight weeks with those who received a matching placebo oil. They found that children who received CBD showed no greater improvement in behavioral scores than those given the placebo. By the end of treatment, average irritability scores dropped from 32.2 to 21.7 in the CBD group and from 30 to 19.2 in the placebo group; this difference wasn't significant.

Does the demand match the efficacy?

Severe behavioral problems such as irritability, aggression, a tendency to self-harm and running away from home are common among children and teens with intellectual disability. They can not only affect children's personal lives but also bleed into their social lives, holding them back from learning, limiting daily functioning and lowering quality of life.

CBD oil offers no behavioral benefit for youths with intellectual disability, finds new study
Dot Plot Showing Subgroup Results of Cannabidiol (CBD) vs. Placebo for Behavioral Problems in Youths With Intellectual Disabilities. Credit: JAMA Pediatrics (2026). DOI: 10.1001/jamapediatrics.2026.5152

To manage these issues, doctors often turn to antipsychotics, stimulants and antidepressants, even though evidence for their effectiveness is limited and the risk of side effects is high. This has fueled interest in safer alternatives, including medicinal cannabis. CBD, in particular, has caught the attention of families and clinicians as a non-intoxicating compound that might ease anxiety and agitation without the same burden of side effects. Yet, despite growing enthusiasm, good-quality evidence that CBD-based medicines actually work remains scarce.

The researchers recruited 131 children and teenagers aged 6–18 who had an intellectual disability and severe behavioral problems from across three children's hospitals in Australia. The trial randomly assigned participants to receive either pure CBD oil or a matching placebo. Neither the children, their families nor the doctors knew who was receiving which treatment until the trial ended, making it a double-blind study.

Parents rated their children's behavior at the start and end of the eight-week maintenance phase, tracking changes in irritability, anxiety, sleep, social interactions and even their own parenting stress.

Both CBD oil and placebo groups showed similar improvements in behavioral problems. The compound also offered no added benefit for anxiety, sleep disturbances, social withdrawal or parenting stress.

Side effects such as diarrhea, tiredness and vomiting were similarly common in both groups, affecting 63% of children taking CBD and 61% receiving the placebo. Although uncommon, temporary spikes in liver enzymes were more frequent among children taking CBD than those receiving the placebo (4.6% vs. 1.5%), especially when taken alongside the antiseizure drug sodium valproate.

The findings raise an important question about whether CBD is worth the cost and potential risks when it offers no greater improvement than a placebo. Clinicians could use the results to help families weigh its uncertain benefits against possible drug interactions.

Written for you by our author Sanjukta Mondal, edited by Gaby Clark, and fact-checked and reviewed by Robert Egan—this article is the result of careful human work. We rely on readers like you to keep independent science journalism alive. If this reporting matters to you, please consider a donation (especially monthly). You'll get an ad-free account as a thank-you.

Publication details

Daryl Efron et al., Cannabidiol for Severe Behavioral Problems in Youths With Intellectual Disability, JAMA Pediatrics (2026). DOI: 10.1001/jamapediatrics.2026.5152

Journal information: JAMA Pediatrics

Who's behind this story?

Sanjukta Mondal

Sanjukta Mondal

Master's in Chemistry. Freelance science journalist and communicator. Published in Chemistry World, BioSpace, and The Hindu. Full profile →

Gaby Clark

Gaby Clark

MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →

Robert Egan

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

© 2026 Science X Network

Citation: CBD oil offers no behavioral benefit for youths with intellectual disability, new study finds (2026, November 18) retrieved 18 November 2026 from https://medicalxpress.com/news/2026-11-cbd-oil-behavioral-benefit-youths.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com